Positive results from influenza human challenge study conducted by hVIVO Pneumagen to advance antiviral candidate into further clinical studies

Strong first-half performance and record forward visibility  Upgrade of Full Year Revenue and EBITDA Guidance

Plans for a new larger state-of-the-art facility to meet growing demand

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for

Strong first-half performance and record order book On track to deliver full-year guidance and long-term sustainable growth

£13.1m contract with the global pharmaceutical client to develop an influenza B virus challenge model

hVIVO to develop human metapneumovirus (hMPV) challenge model First client of the new hMPV model secured

hVIVO plc (AIM & Euronext: HVO), formerly known as Open Orphan plc, and a global leader in conducting human challenge clinical trials for infectious and respiratory disease products, has announced

SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).

Transformational year with record EBITDA underlining strong operational delivery